Skip to content

Medical emergency? What to do

Merck cancer vaccine faces Christian-right scrutiny

3-RXPublished May 22, 20064 min read

Key points

  • Inc.'s vaccine to prevent the world's most prevalent sexually transmitted infection sailed through a panel of U.S. health experts, despite early fears of opposition from the Christian Right that it might lead to promiscuity and a false sense of security.
  • But Merck may ultimately find itself at loggerheads with those same groups as it seeks to make the vaccine mandatory for school admission, a step considered key for widespread acceptance and one that many of the groups oppose.
  • "We don't think it should be made mandatory for school attendance," said Peter Sprigg, vice president of policy at the Family Research Council, who attended the Food and Drug Administration (FDA) advisory panel meeting on Thursday.
  • "We support the widespread availability of the vaccine, but we do oppose the mandatory vaccination for entry to public school," said Linda Klepacki, an analyst for sexual health for the group.

Merck & Co. Inc.'s vaccine to prevent the world's most prevalent sexually transmitted infection sailed through a panel of U.S. health experts, despite early fears of opposition from the Christian Right that it might lead to promiscuity and a false sense of security.

The drugmaker's efforts to educate Christian groups while touting the vaccine's top selling point -- prevention of cervical cancer -- helped win them over.

But Merck may ultimately find itself at loggerheads with those same groups as it seeks to make the vaccine mandatory for school admission, a step considered key for widespread acceptance and one that many of the groups oppose.

The vaccine, known as Gardasil, with an estimated $2 billion U.S. market potential, targets four types of sexually transmitted human papilloma virus (HPV), which causes more than 70 percent of cervical cancer cases and 90 percent of genital warts.

"We don't think it should be made mandatory for school attendance," said Peter Sprigg, vice president of policy at the Family Research Council, who attended the Food and Drug Administration (FDA) advisory panel meeting on Thursday.

That view is shared by evangelical Christian group Focus on the Family.

"We support the widespread availability of the vaccine, but we do oppose the mandatory vaccination for entry to public school," said Linda Klepacki, an analyst for sexual health for the group.

For Gardasil to be widely adopted, Merck must first win FDA approval. Then, it must garner widespread backing from the Advisory Committee on Immunization Practices -- a group that advises the U.S. Centers for Disease Control and Prevention on immunization standards. Both Merck and analysts deem widespread backing likely.

States would then consider whether it should be included in the list of vaccinations required for school admission.

"This is a disease that is completely sexually transmitted," Klepacki said, unlike the mumps or measles, which can be transmitted by casual contact. "We believe that parents should have the final say on whether to vaccinate their children."

KEY PRODUCT FOR MERCK

Merck faces a host of product liability lawsuits over its withdrawn arthritis drug Vioxx and imminent generic competition for its cholesterol drug Zocor, so the company has a lot riding on the success of Gardasil.

If the FDA follows the unanimous recommendation of its expert panel, which is widely expected, Merck will launch Gardasil in June.

That would give Merck at least a one-year advantage over GlaxoSmithKline Plc, which is developing its own HPV vaccine called Cervarix.

Cervical cancer is the second most common cause of cancer deaths worldwide. There are nearly a half million diagnoses and 240,000 deaths each year, Merck said.

"Obviously, we believe school requirements are a very positive intervention because they do help to increase access on a state-by-state level to vaccines, especially for something as important as cervical cancer," Merck spokeswoman Kelly Dougherty said.

She said Merck would give state health officials data and information about the vaccine -- the same approach it used to win initial backing from Christian groups.

The Family Research Council's Sprigg said Merck met extensively with his group to address concerns that the vaccine might encourage promiscuous behavior by providing a false sense of protection against sexually transmitted disease.

"From the material being reported thus far, we are being told that they have not found that effect," Sprigg said, adding, "We are monitoring this."

Dr. Gene Rudd of the Christian Medical and Dental Associations, which also supports the vaccine but opposes school mandates, said he believes states could resolve the matter by building in some wiggle room.

"Our position is to have an easy opt out," he said. "Make it mandatory in the sense that it is generally accepted, but parents can opt out."

"TELL SOMEONE"

While Merck awaits FDA approval, it is getting the word out about Gardasil. The company started seeding the U.S. market last month with an informational advertising blitz stressing the link between HPV and cervical cancer.

Merck said it would continue its education efforts while regulatory agencies around the world review the product.

A U.S. television and print campaign, with the tag line "Tell Someone," makes no mention of the company or the vaccine, but Merck is now considering how to integrate the vaccine into its promotional materials, said Bev Lybrand, vice president of marketing.

She said the campaign was "born out of the finding that very little awareness exists among women about HPV and its consequences."

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.